CSF 水平的 YKL-40 在 MS 中增加，并取代免疫抑制治疗。
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
机构信息
Department of Neurology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom.
出版信息
J Neuroimmunol. 2014 Apr 15;269(1-2):87-9. doi: 10.1016/j.jneuroim.2014.02.004. Epub 2014 Feb 13.
The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to immunosuppressive treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by immunosuppressive treatment.
胶质细胞在多发性硬化症（MS）不同阶段的作用尚不清楚。为了监测胶质细胞的激活，我们分析了 MS 患者在不同疾病阶段和免疫抑制治疗后的生物标志物 YKL-40 和 sCD14 在脑脊液（CSF）中的水平。与健康对照组相比，复发期、缓解期和继发性进展期 MS 患者 CSF 中的 YKL-40 水平升高。此外，米托蒽醌和那他珠单抗治疗后 CSF 中的 YKL-40 水平降低。CSF 中 sCD14 的水平没有差异。因此，我们可以推断出胶质细胞的激活存在于 MS 的所有阶段，并通过免疫抑制治疗而减少。
Zotero 插件